REP 9AC
is the much-anticipated new hepatitis B drug that within weeks
suppresses the
hepatitis B virus, enabling patients to lose the hepatitis B
surface
antigen—something no other drug has been able to do. In this
latest study,
when interferon was added to REP 9AC, patients even developed
surface
antibodies—essentially permanently getting rid of the infection.
—Christine. M. Kukka, Project Manager, HBV Advocate
Source:
"Short Term Immunotherapy Following REP 9AC..." by Al-Mahtab,
Bazinet
and Vaillant. Asian Pacific Association for the Study of Liver
Disease 2013
& 15th annual TIDES meeting.
Read more.....Labels: drugs in development, REP 9AC, treatment